OrbiMed’s Geron GERN Stock Holding History

OrbiMed’s Portfolio GERN Stock Details GERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400,000	Closed	-$1.82M	–	127
2024 Q3	$1.82M	Sell	400,000 -200,000	-33%	-$909K	0.03%	110
2024 Q2	$2.54M	Buy	+600,000	New	+$2.34M	0.05%	100

Other funds holding GERN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's GERN Position: Q1 2025 in Review

OrbiMed sold out of Geron (GERN) in Q1 2025, closing a stake of 2,168,000 shares — an estimated $7.67M sold.

OrbiMed first reported a position in GERN in Q4 2023 and held it in 4 quarters. The position peaked at $42.5M in Q1 2024. 270 funds tracked by Wall St. Rank hold GERN as of Q1 2025.

OrbiMed reported no remaining Geron position as of Q1 2025 after selling out during the quarter.
OrbiMed sold 2,168,000 Geron shares in Q1 2025, an estimated $7.67M.
OrbiMed first reported a position in Geron in Q4 2023 and held it in 4 quarters.
OrbiMed's Geron position peaked at $42.5M in Q1 2024.
270 funds tracked by Wall St. Rank held Geron as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.